Updated Phase I/II Data Show AMT-130 Slows Huntington's Disease Progression by 80% at 36 Months
QURE has more than doubled off its 52-week low of $8.73.
Summary
Updated Phase I/II data for AMT-130 in Huntington's disease showed 80% slowing of disease progression at 36 months (p=0.005) and 61% on TFC at 48 months (p=0.008), reinforcing the BLA submitted earlier this month.
Key Events · Product Development and Regulatory · QURE
-
Updated 36-Month Data Strengthens BLA
Analysis of all 15 high-dose patients showed 80% slowing of disease progression on cUHDRS (p=0.005) and 67% on TFC (p=0.011) at 36 months — the regulatory anchor for the submitted BLA.
-
First 48-Month Data Shows Continued Benefit
In 12 high-dose patients, cUHDRS showed 44% slowing (p=0.144, non-significant) and TFC showed 61% slowing (p=0.008) at 48 months, with dose-dependent response maintained.
-
External Control Limitations Acknowledged
Updated Enroll-HD B control had 53% data missingness at 48 months; post-hoc analysis using prior Enroll-HD A control showed 54% slowing on cUHDRS (p=0.041) and 68% on TFC (p<0.001).
-
Safety Profile Remains Manageable
AMT-130 generally well-tolerated; one suicide in low-dose patient ~5 years post-treatment assessed unrelated to treatment; no new treatment-related SAEs in Cohorts 1 and 2 since September 2025.
Analysis · QURE · Life Sciences
The updated Phase I/II data for AMT-130, uniQure's Huntington's disease gene therapy, strengthen the regulatory case for its already-submitted BLA. The 36-month analysis now includes 15 high-dose patients (up from 12) and shows 80% slowing of disease progression on cUHDRS (p=0.005) and 67% on TFC (p=0.011) — the timepoint anchoring the BLA. First 48-month data showed 44% slowing on cUHDRS (p=0.144, non-significant) and 61% on TFC (p=0.008), with the company arguing the updated external control's 53% data missingness understates the true treatment effect. A post-hoc analysis using the prior control showed 54% and 68% slowing respectively. Safety remains generally well-tolerated, with one suicide in a low-dose patient assessed as unrelated to treatment. This data directly supports the BLA submitted September 2, 2026 and the MAA to UK MHRA, and comes as the company seeks accelerated approval for the first disease-modifying therapy in Huntington's disease.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QURE was trading at $22.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $8.73 to $71.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.